USP <800> hazardous drug compliance became a fully enforceable compendial standard on November 1, 2023, and the pharmacies most exposed are the ones that treated containment as a one-time build-out rather than an ongoing assessment of risk. The chapter reaches any entity that receives, stores, prepares, administers, or disposes of a drug on the NIOSH hazardous drug list, not compounding pharmacies alone. A gap between what a pharmacy's containment plan describes and what an inspector finds at the bench produces a documented finding, and that finding follows the pharmacy through an FDA inspection, a state board review, and a PBM network audit alike.
What USP 800 Requires
USP <800> sits alongside USP 795 and USP 797 as one of three compounding chapters, together known as USP 797/800, that reached final enforceable status the same day. The chapter adopts NIOSH's hazard criteria: carcinogenicity, teratogenicity or developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or a structure and toxicity profile that mimics an existing hazardous drug. Pharmacies compounding under the 503A vs 503B framework must maintain a current hazardous drug list, personnel training and competency records, and cGMP-adjacent facility and engineering controls. NIOSH published its first update to the List of Hazardous Drugs in Healthcare Settings since 2016, adding 25 drugs and removing seven, including liraglutide, which NIOSH determined no longer met the criteria for occupational hazard. A pharmacy relying on the prior list is out of compliance the day the update publishes.
The Assessment of Risk Exception
USP <800> permits a written assessment of risk to support alternative containment strategies for specific dosage forms, primarily final, manufacturer-sealed dosage forms of non-antineoplastic hazardous drugs, reproductive-hazard-only drugs, and antineoplastics that staff only count or package without manipulation. The assessment of risk is a drug-by-drug analysis covering dosage form, packaging, degree of manipulation, and personnel exposure potential, and it has to stay current as the hazardous drug list changes. Pharmacies that treat the assessment of risk as a document filed once, rather than a record updated with every NIOSH revision, are the ones inspectors flag first.
Containment Requirements Inspectors Check First
The containment primary engineering control, the ventilated biological safety cabinet or compounding aseptic containment isolator that uses airflow capture and HEPA filtration to contain a hazardous drug during handling, sits inside the containment secondary engineering control: a hazardous drug room with fixed walls, external venting, and negative pressure relative to adjacent spaces. Inspectors verify pressure differential logs and venting certification, not just the presence of the equipment on a floor plan. A cabinet that is present but uncertified, or a room that shares airspace with routine dispensing, draws the same finding as equipment that was never installed.
A hazardous drug room that shares airspace with routine dispensing carries the same inspection exposure as a missing containment cabinet.
Where the Inspection Findings Land
FDA applies its 2020 guidance on insanitary conditions at compounding facilities to hazardous drug handling as one basis for finding a compounded drug adulterated under the Federal Food, Drug, and Cosmetic Act, and a containment-related Form 483 observation can escalate to a warning letter if the pharmacy's response inside the 15-day response window is incomplete. State boards of pharmacy, which enforce USP <800> as adopted rule, layer their own findings on top: missing beyond-use dating documentation on hazardous compounds, incomplete personnel training files, or an assessment of risk that was never updated after the current NIOSH revision. Any one of these can support a summary suspension of a pharmacy's sterile or hazardous compounding permit before a hearing is scheduled.
Why Early Legal Counsel Is Critical
It is critical that pharmacies promptly retain experienced healthcare defense counsel upon receiving an FDA Form 483 observation, a warning letter, or a state board notice of hazardous drug containment deficiencies. Early legal involvement protects the pharmacy's rights during the inspection response window, prevents staff statements to inspectors from becoming admissions used against the pharmacy later, and preserves defenses, such as a documented and dated assessment of risk, that are far harder to establish once a formal enforcement record exists. Waiting until a warning letter escalates to a consent decree, or a board finding escalates to a hearing, narrows the options counsel can bring to the matter.
How Health Law Alliance Can Help
Health Law Alliance defends compounding pharmacies nationwide against USP <800> findings, from an FDA Form 483 observation through a state board hazardous drug compliance review, building the assessment of risk documentation and containment record a pharmacy needs before the next inspection as well as the defense record after one. If your pharmacy has received an inspection finding tied to hazardous drug handling, contact our compounding pharmacy defense team for a free, confidential consultation.
